| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5546567 | Acta Pharmaceutica Sinica B | 2017 | 8 Pages |
Abstract
Syringaresinol-4-O-β-D-glucoside (SSG) is a promising candidate for the prevention and treatment of metabolic disorder. This study demonstrated that SSG has regulative effect on lipogenesis and glucose consumption in vitro. Mechanism studies revealed that the beneficial effects were associated with regulating the expression and transcription of lipid and glucose related genes.486
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Drug Discovery
Authors
Shuai Wang, Chongming Wu, Xin Li, Yue Zhou, Quanyang Zhang, Fuchao Ma, Jianhe Wei, Xiaopo Zhang, Peng Guo,